Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment [Phase 3]

View source ↗

Summary

This Phase 3 trial is evaluating the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia who failed first-line treatment. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Sanofi | Conditions: Immune Thrombocytopenia | Phase 3 | Status: RECRUITING